Diamedica Therapeutics Stock News

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 69,600 shares, a decline of 21.5% from the October 31st total of 88,700 shares. Based on an average trading volume of 201,900 shares, the short-interest ratio is currently 0.3 days. Approximately 0.4% of []

DiaMedica Therapeutics (OTCMKTS:DMCAF) and Aytu Biopharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk DiaMedica Therapeutics has a beta of -0.02, meaning that its stock price []

Analysts expect DiaMedica Therapeutics Inc. (NASDAQ:DMAC) to post earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for DiaMedica Therapeutics earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.15). DiaMedica Therapeutics reported earnings per []

DiaMedica Therapeutics (NASDAQ:DMAC) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends. Earnings & Valuation This table compares DiaMedica Therapeutics and Akouos top-line revenue, earnings per share and []

DiaMedica Therapeutics (NASDAQ:DMAC) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings. Insider & Institutional Ownership 54.7% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 95.2% []

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, President and CEO, will participate in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings. A recording of the presentation will be available beginning on Monday, Nove

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2021 Results - Earnings Call Transcript

Looking for penny stocks on Reddit? Check these 5 out The post Penny Stocks to Buy Now?

DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial. Their drug, DM199, i

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurr